$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased ...








    



            







    
        
            February 05, 2026 08:30 ET
        

        
             | Source:
            

                Strata Critical Medical, Inc
            
                

        
    

    

    

    





        
$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditionsOwned aircraft excluded from collateral package and remain unencumbered  NEW YORK, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).  “This facility will improve Strata’s capital efficiency, enabling deployment of more cash towards attractive acquisition opportunities,” said Amir Cohen, Strata’s Chief Accounting and Integration Officer. “By leaving our owned aircraft fleet unencumbered, we are maintaining significant optionality for additional financing in the future.”  “We have a strong track record of successful tuck-in acquisitions in the clinical perfusion space,” said Mat Schneider, CFO of Strata’s Clinical division and VP, IR. “This new facility will enable us to continue executing on our time-tested playbook to accelerate growth.”  About Strata Critical Medical, Inc.  Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.  Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.  For more information, visit www.srta.com.  Contacts  Mathew Schneiderinvestors@srta.com  
            

SRTA

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Strata Critical Medical has established a $30 million asset-based revolving credit facility with JPMorgan Chase, potentially increasing to $50 million. This financing will enhance capital efficiency for strategic acquisitions, positioning Strata for accelerated growth in the organ transplant sector.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Strata secured a $30 million ABL facility from JPMorgan Chase.</li><li>Facility can expand to $50 million under certain conditions.</li><li>Funding will enhance capital efficiency for acquisitions.</li><li>Unencumbered aircraft fleet maintains financial flexibility.</li><li>Strata aims to leverage acquisitions in clinical perfusion space.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>JPMorgan Chase Bank (JPM)</strong>: Provided the credit facility that enables SRTA&#039;s growth strategy.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under Corporate Developments as it signifies a strategic financial move that positions Strata for acquisitions, which is crucial in maintaining a competitive edge in the healthcare logistics sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The $30 million ABL facility could boost SRTA’s competitive position in medical logistics.</li><li>Increase of facility to $50 million signals strong future acquisition potential.</li><li>Strategic acquisitions may enhance revenue streams in clinical perfusion.</li><li>Unencumbered aircraft assets provide operational flexibility for future financing needs.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Strata announced a $30 million ABL facility on February 5, 2026.</li><li>Facility could expand to $50 million based on conditions.</li><li>Facility aims to improve capital efficiency for acquisitions.</li><li>Strata operates one of U.S.&#039;s largest organ transport networks.</li><li>Recent executive quotes indicate a focus on growth through acquisitions.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy SRTA due to increased acquisition capabilities expected to drive growth within the next 12 months.</p>
  </section>
</section>


<article>
    <header>
        <h1>Strata Critical Medical, Inc. Closes $30 Million Revolving Credit Facility to Enhance Acquisition Strategy</h1>
        <p><strong>Date:</strong> February 05, 2026 | <strong>Source:</strong> GlobeNewsWire</p>
    </header>
    <section>
        <h2>Overview of the ABL Facility</h2>
        <p>Strata Critical Medical, Inc. (Nasdaq: <strong>SRTA</strong>) announced the successful closing of a $30 million asset-based revolving credit facility with JPMorgan Chase Bank, N.A. This facility can potentially be expanded to $50 million, subject to specific conditions. Notably, the credit facility will be undrawn at the time of closing, allowing Strata to maneuver efficiently in the capital markets.</p>
    </section>
    
    <section>
        <h2>Strategic Implications for Strata</h2>
        <p>The establishment of this <strong>ABL Facility</strong> is designed to significantly enhance Strata's capital efficiency. According to Amir Cohen, Chief Accounting and Integration Officer at Strata, “This facility will improve Strata’s capital efficiency, enabling deployment of more cash towards attractive acquisition opportunities.” By maintaining their owned aircraft fleet unencumbered, Strata aims to preserve strategic financing options for future expansions.</p>
    </section>
    
    <section>
        <h2>Insight from Leadership</h2>
        <p>Mat Schneider, CFO of Strata’s Clinical division and VP of Investor Relations, expressed confidence in the new funding, stating, “We have a strong track record of successful tuck-in acquisitions in the clinical perfusion space. This new facility will enable us to continue executing on our time-tested playbook to accelerate growth.” Such remarks underscore Strata's commitment to fostering its acquisition strategy in the organ transplant market.</p>
    </section>
    
    <section>
        <h2>About Strata Critical Medical, Inc.</h2>
        <p>Strata Critical Medical specializes in providing time-critical logistics and medical services within the U.S. healthcare sector. The company operates one of the largest air transport and surgical service networks, catering specifically to transplant hospitals and organ procurement organizations. Strata's integrated “one call” solution is dedicated to enhancing donor organ recovery.</p>
        
        <h3>Core Services</h3>
        <ul>
            <li>Air and ground logistics</li>
            <li>Surgical organ recovery</li>
            <li>Organ placement and normothermic regional perfusion</li>
            <li>Pertaining to cardiovascular surgery centers under Trinity Medical Solutions and Keystone Perfusion brands</li>
        </ul>
    </section>
    
    <footer>
        <p>For more information about Strata Critical Medical, Inc., visit <a href="http://www.srta.com">www.srta.com</a>.</p>
        <p>Contact: Mathew Schneider, Email: <a href="mailto:investors@srta.com">investors@srta.com</a></p>
    </footer>
</article>

Strata Critical Medical has established a $30 million asset-based revolving credit facility with JPMorgan Chase, potentially increasing to $50 million. This financing will enhance capital efficiency for strategic acquisitions, positioning Strata for accelerated growth in the organ transplant sector.

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News